SNIPP study - Efficacy and safety of Sunitinib in patients with paraganglioma/pheochromocytoma
- Conditions
- Paraganglioma/pheochromocytomaMedDRA version: 14.0Level: LLTClassification code 10034876Term: PheochromocytomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2011-003163-29-NL
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- 28
Inclusion Criteria
- Metastatic or unresectable malignant paraganglioma or pheochromocytoma
- Progressive disease
- ECOG 0-2
- Age > 18 years
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 14
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 14
Exclusion Criteria
- Known brain metastases
- Concurrent treatment with other anti-cancer therapy
- Cardiovascular co-morbidity
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method